基于对比增强CT影像组学预测T4期胃癌患者腹膜复发及腹腔热灌注化疗获益
本研究回顾性纳入245例T4期胃癌根治术后患者,从对比增强CT提取1343个影像组学特征计算RadScore,并联合临床病理特征构建联合风险评分。联合风险评分预测腹膜复发的测试队列AUC为0.820,优于RadScore的0.726;高联合风险评分患者更可能从预防性腹腔热灌注化疗中获益(HR 0.490)。
要点
- 联合风险评分预测腹膜复发测试队列AUC为0.820,优于RadScore的0.726(NRI 0.446,p<0.01)。
- RadScore识别腹膜复发高风险患者的测试队列AUC为0.726,HR为3.088。
- 高联合风险评分T4期胃癌患者更可能从预防性腹腔热灌注化疗中获益(HR 0.490)。
核心结论
- 整合影像生物标志物与临床病理特征的联合风险评分可较精确识别T4期胃癌腹膜复发高风险患者,风险评分较高者更可能从预防性腹腔热灌注化疗中获益。
研究设计与样本
- 回顾性纳入245例接受根治性胃切除术的T4期胃癌患者(年龄60.54±9.79岁,177例男性),从每个归一化对比增强CT序列提取1343个影像组学特征,通过集成机器学习框架计算RadScore并联合临床病理特征构建联合风险评分。
诊断标准与关键数值
- RadScore预测腹膜复发:测试队列AUC为0.726,HR为3.088。
- 联合风险评分预测腹膜复发:测试队列AUC为0.820,NRI为0.446,p<0.01。
- 高联合风险评分患者预防性腹腔热灌注化疗获益:HR为0.490。
临床应用与阅片要点
- 联合风险评分整合影像组学与临床病理特征,可用于识别T4期胃癌术后腹膜复发高风险患者。
- 联合风险评分较高的T4期胃癌患者更可能从预防性腹腔热灌注化疗中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aimed to predict post-surgical peritoneal recurrence (PR) and the preventative effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in T4 gastric cancer (GC) patients using CT radiomics and clinical features.
MATERIALS AND METHODS: Patients with T4 GC who underwent radical gastrectomy were retrospectively enrolled. A total of 1343 radiomics features were extracted from each normalized contrast-enhanced CT series. The radiomics score (RadScore) was computed via an ensembled machine learning framework to predict the risk of PR. We also generated a combined risk score by integrating the RadScore and clinicopathological features. The performance for predicting PR was evaluated by the area under the curve (AUC), Kaplan-Meier analysis, c-index, and decision curve analysis. The performance for predicting HIPEC benefits was evaluated via Kaplan-Meier analysis and interaction analysis.
RESULTS: A total of 245 T4 GC patients (aged 60.54 ± 9.79 years, 177 men) were enrolled in this study. The RadScore could identify patients at high risk of PR with moderate accuracy (test cohort AUC: 0.726; [HR]: 3.088). The combined risk score outperformed the RadScore in predicting PR (test cohort AUC: 0.820, net reclassification index: 0.446, p < 0.01). T4 GC patients with high combined risk scores are more likely to benefit from prophylactic HIPEC ([HR]: 0.490).
CONCLUSION: The combined risk score integrating imaging biomarkers and clinicopathological traits could precisely identify T4 GC patients at high risk of PR. Patients with higher risk scores are more likely to benefit from prophylactic HIPEC.
引用
- Jiang Z, Yang M, Jiang S, et al. Predicting peritoneal recurrence and hyperthermic intraperitoneal chemotherapy benefits in T4 gastric cancer patients via contrast-enhanced CT radiomics. Eur J Radiol. 2025. PMID: 40738014. doi:10.1016/j.ejrad.2025.112333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。